The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study

Elizabeth Schneider; Maartje S. Spetter; Elizabeth Martin; Elizabeth Sapey; Kay Por Yip; Konstantinos N. Manolopoulos; Abd A. Tahrani; Jason M. Thomas; Michelle Lee; Manfred Hallschmid; Pia Rotshtein; Colin T. Dourish; Suzanne Higgs

doi:10.1038/s41366-022-01115-1

The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study

Elizabeth Schneider, Maartje S. Spetter, Elizabeth Martin, Elizabeth Sapey, Kay Por Yip, Konstantinos N. Manolopoulos, Abd A. Tahrani, Jason M. Thomas, Michelle Lee, Manfred Hallschmid, Pia Rotshtein, Colin T. Dourish, Suzanne Higgs^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

55 Downloads (Pure)

Abstract

Background/Objectives: Intranasal (IN) administration of insulin decreases appetite in humans, but the underlying mechanisms are unclear, and it is unknown whether IN insulin affects the food intake of women with obesity. Subjects/Methods: In a double-blind, placebo-controlled, crossover design, participants (35 lean women and 17 women with obesity) were randomized to receive 160 IU/1.6 mL of IN insulin or placebo in a counterbalanced order in the post prandial state. The effects of IN insulin on cookie intake, appetite, mood, food reward, cognition and neural activity were assessed. Results: IN insulin in the post prandial state reduced cookie intake, appetite and food reward relative to placebo and these effects were more pronounced for women with obesity compared with lean women. IN insulin also improved mood in women with obesity. In both BMI groups, IN insulin increased neural activity in the insula when viewing food pictures. IN insulin did not affect cognitive function. Conclusions: These results suggest that IN insulin decreases palatable food intake when satiated by reducing food reward and that women with obesity may be more sensitive to this effect than lean women. Further investigation of the therapeutic potential of IN insulin for weight management in women with obesity is warranted.

Original language	English
Pages (from-to)	1319-1327
Number of pages	9
Journal	International Journal of Obesity
Volume	46
Issue number	7
Early online date	9 Apr 2022
DOIs	https://doi.org/10.1038/s41366-022-01115-1
Publication status	Published - Jul 2022

Bibliographical note

Funding Information:
Funding for this work was provided by BBSRC Grant UK awarded to SH grant number: BB/N008847/1 and supported by the NIHR funded Birmingham Clinical Research Facility. The BBSRC/NIHR had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The behavioural results of this study have been previously presented in poster format at the American College of Neuropsychopharmacology conference in 2019 and the European College of Neuropsychopharmacology conference in 2020. We would like to thank Nina Avitable, Jennie Gavin, Hafwen Thornhill, Saleema Islam, Dr Ross Wilson, and Nina Salman for their invaluable assistance with data collection.

Competing interests:
AAT reports grants from Novo Nordisk, personal fees from Novo Nordisk, non-financial support from Novo Nordisk, personal fees from Eli Lilly, non-financial support from Eli Lilly, personal fees from Janssen, personal fees from AstraZeneca, non-financial support from AstraZeneca, non-financial support from Impeto medical, non-financial support from Resmed, non-financial support from Aptiva, personal fees from Boehringer Ingelheim, non-financial support from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, nonfinancial support from Bristol Myers Squibb, personal fees from NAPP, non-financial support from NAPP, personal fees from Merck Sharp & Dohme, non-financial support from Merck Sharp & Dohme, personal fees from Nestle, personal fees from Gilead, grants from Sanofi, and personal fees from Sanofi outside the submitted work. AAT is currently an employee of Novo Nordisk. This work was performed before AAT became a Novo Nordisk employee. Novo Nordisk had no role in this study. CTD is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. All other authors declare no competing interests.

Publisher Copyright:
© 2022, The Author(s).

Keywords

Feeding behaviour
Translational research
Appetite
Insulin/pharmacology
Obesity
Double-Blind Method
Humans
Biomedical Research
Female
Administration, Intranasal
Energy Intake

ASJC Scopus subject areas

Nutrition and Dietetics
Medicine (miscellaneous)
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41366-022-01115-1Licence: Creative Commons: Attribution (CC BY)

schneidere2022effectFinal published version, 2.06 MBLicence: Creative Commons: Attribution (CC BY)

Interactions between metabolic, cognitive and reward processes in appetite
Rotshtein, P. & Higgs, S.
3/10/16 → 1/10/20
Project: Research Councils

Cite this

Schneider, E., Spetter, M. S., Martin, E., Sapey, E., Yip, K. P., Manolopoulos, K. N., Tahrani, A. A., Thomas, J. M., Lee, M., Hallschmid, M., Rotshtein, P., Dourish, C. T., & Higgs, S. (2022). The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study. International Journal of Obesity, 46(7), 1319-1327. Advance online publication. https://doi.org/10.1038/s41366-022-01115-1

@article{de0587f4a333426e85ab0ffc202c753c,

title = "The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study",

abstract = "Background/Objectives: Intranasal (IN) administration of insulin decreases appetite in humans, but the underlying mechanisms are unclear, and it is unknown whether IN insulin affects the food intake of women with obesity. Subjects/Methods: In a double-blind, placebo-controlled, crossover design, participants (35 lean women and 17 women with obesity) were randomized to receive 160 IU/1.6 mL of IN insulin or placebo in a counterbalanced order in the post prandial state. The effects of IN insulin on cookie intake, appetite, mood, food reward, cognition and neural activity were assessed. Results: IN insulin in the post prandial state reduced cookie intake, appetite and food reward relative to placebo and these effects were more pronounced for women with obesity compared with lean women. IN insulin also improved mood in women with obesity. In both BMI groups, IN insulin increased neural activity in the insula when viewing food pictures. IN insulin did not affect cognitive function. Conclusions: These results suggest that IN insulin decreases palatable food intake when satiated by reducing food reward and that women with obesity may be more sensitive to this effect than lean women. Further investigation of the therapeutic potential of IN insulin for weight management in women with obesity is warranted.",

keywords = "Feeding behaviour, Translational research, Appetite, Insulin/pharmacology, Obesity, Double-Blind Method, Humans, Biomedical Research, Female, Administration, Intranasal, Energy Intake",

author = "Elizabeth Schneider and Spetter, {Maartje S.} and Elizabeth Martin and Elizabeth Sapey and Yip, {Kay Por} and Manolopoulos, {Konstantinos N.} and Tahrani, {Abd A.} and Thomas, {Jason M.} and Michelle Lee and Manfred Hallschmid and Pia Rotshtein and Dourish, {Colin T.} and Suzanne Higgs",

note = "Funding Information: Funding for this work was provided by BBSRC Grant UK awarded to SH grant number: BB/N008847/1 and supported by the NIHR funded Birmingham Clinical Research Facility. The BBSRC/NIHR had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The behavioural results of this study have been previously presented in poster format at the American College of Neuropsychopharmacology conference in 2019 and the European College of Neuropsychopharmacology conference in 2020. We would like to thank Nina Avitable, Jennie Gavin, Hafwen Thornhill, Saleema Islam, Dr Ross Wilson, and Nina Salman for their invaluable assistance with data collection. Competing interests: AAT reports grants from Novo Nordisk, personal fees from Novo Nordisk, non-financial support from Novo Nordisk, personal fees from Eli Lilly, non-financial support from Eli Lilly, personal fees from Janssen, personal fees from AstraZeneca, non-financial support from AstraZeneca, non-financial support from Impeto medical, non-financial support from Resmed, non-financial support from Aptiva, personal fees from Boehringer Ingelheim, non-financial support from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, nonfinancial support from Bristol Myers Squibb, personal fees from NAPP, non-financial support from NAPP, personal fees from Merck Sharp & Dohme, non-financial support from Merck Sharp & Dohme, personal fees from Nestle, personal fees from Gilead, grants from Sanofi, and personal fees from Sanofi outside the submitted work. AAT is currently an employee of Novo Nordisk. This work was performed before AAT became a Novo Nordisk employee. Novo Nordisk had no role in this study. CTD is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. All other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jul,

doi = "10.1038/s41366-022-01115-1",

language = "English",

volume = "46",

pages = "1319--1327",

journal = "International Journal of Obesity",

issn = "0307-0565",

publisher = "Nature Publishing Group",

number = "7",

}

Schneider, E, Spetter, MS, Martin, E, Sapey, E , Yip, KP, Manolopoulos, KN, Tahrani, AA, Thomas, JM, Lee, M, Hallschmid, M, Rotshtein, P, Dourish, CT & Higgs, S 2022, 'The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study', International Journal of Obesity, vol. 46, no. 7, pp. 1319-1327. https://doi.org/10.1038/s41366-022-01115-1

TY - JOUR

T1 - The effect of intranasal insulin on appetite and mood in women with and without obesity

T2 - an experimental medicine study

AU - Schneider, Elizabeth

AU - Spetter, Maartje S.

AU - Martin, Elizabeth

AU - Sapey, Elizabeth

AU - Yip, Kay Por

AU - Manolopoulos, Konstantinos N.

AU - Tahrani, Abd A.

AU - Thomas, Jason M.

AU - Lee, Michelle

AU - Hallschmid, Manfred

AU - Rotshtein, Pia

AU - Dourish, Colin T.

AU - Higgs, Suzanne

N1 - Funding Information: Funding for this work was provided by BBSRC Grant UK awarded to SH grant number: BB/N008847/1 and supported by the NIHR funded Birmingham Clinical Research Facility. The BBSRC/NIHR had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The behavioural results of this study have been previously presented in poster format at the American College of Neuropsychopharmacology conference in 2019 and the European College of Neuropsychopharmacology conference in 2020. We would like to thank Nina Avitable, Jennie Gavin, Hafwen Thornhill, Saleema Islam, Dr Ross Wilson, and Nina Salman for their invaluable assistance with data collection. Competing interests: AAT reports grants from Novo Nordisk, personal fees from Novo Nordisk, non-financial support from Novo Nordisk, personal fees from Eli Lilly, non-financial support from Eli Lilly, personal fees from Janssen, personal fees from AstraZeneca, non-financial support from AstraZeneca, non-financial support from Impeto medical, non-financial support from Resmed, non-financial support from Aptiva, personal fees from Boehringer Ingelheim, non-financial support from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, nonfinancial support from Bristol Myers Squibb, personal fees from NAPP, non-financial support from NAPP, personal fees from Merck Sharp & Dohme, non-financial support from Merck Sharp & Dohme, personal fees from Nestle, personal fees from Gilead, grants from Sanofi, and personal fees from Sanofi outside the submitted work. AAT is currently an employee of Novo Nordisk. This work was performed before AAT became a Novo Nordisk employee. Novo Nordisk had no role in this study. CTD is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. All other authors declare no competing interests. Publisher Copyright: © 2022, The Author(s).

PY - 2022/7

Y1 - 2022/7

N2 - Background/Objectives: Intranasal (IN) administration of insulin decreases appetite in humans, but the underlying mechanisms are unclear, and it is unknown whether IN insulin affects the food intake of women with obesity. Subjects/Methods: In a double-blind, placebo-controlled, crossover design, participants (35 lean women and 17 women with obesity) were randomized to receive 160 IU/1.6 mL of IN insulin or placebo in a counterbalanced order in the post prandial state. The effects of IN insulin on cookie intake, appetite, mood, food reward, cognition and neural activity were assessed. Results: IN insulin in the post prandial state reduced cookie intake, appetite and food reward relative to placebo and these effects were more pronounced for women with obesity compared with lean women. IN insulin also improved mood in women with obesity. In both BMI groups, IN insulin increased neural activity in the insula when viewing food pictures. IN insulin did not affect cognitive function. Conclusions: These results suggest that IN insulin decreases palatable food intake when satiated by reducing food reward and that women with obesity may be more sensitive to this effect than lean women. Further investigation of the therapeutic potential of IN insulin for weight management in women with obesity is warranted.

AB - Background/Objectives: Intranasal (IN) administration of insulin decreases appetite in humans, but the underlying mechanisms are unclear, and it is unknown whether IN insulin affects the food intake of women with obesity. Subjects/Methods: In a double-blind, placebo-controlled, crossover design, participants (35 lean women and 17 women with obesity) were randomized to receive 160 IU/1.6 mL of IN insulin or placebo in a counterbalanced order in the post prandial state. The effects of IN insulin on cookie intake, appetite, mood, food reward, cognition and neural activity were assessed. Results: IN insulin in the post prandial state reduced cookie intake, appetite and food reward relative to placebo and these effects were more pronounced for women with obesity compared with lean women. IN insulin also improved mood in women with obesity. In both BMI groups, IN insulin increased neural activity in the insula when viewing food pictures. IN insulin did not affect cognitive function. Conclusions: These results suggest that IN insulin decreases palatable food intake when satiated by reducing food reward and that women with obesity may be more sensitive to this effect than lean women. Further investigation of the therapeutic potential of IN insulin for weight management in women with obesity is warranted.

KW - Feeding behaviour

KW - Translational research

KW - Appetite

KW - Insulin/pharmacology

KW - Obesity

KW - Double-Blind Method

KW - Humans

KW - Biomedical Research

KW - Female

KW - Administration, Intranasal

KW - Energy Intake

UR - http://www.scopus.com/inward/record.url?scp=85127680959&partnerID=8YFLogxK

U2 - 10.1038/s41366-022-01115-1

DO - 10.1038/s41366-022-01115-1

M3 - Article

C2 - 35397638

AN - SCOPUS:85127680959

SN - 0307-0565

VL - 46

SP - 1319

EP - 1327

JO - International Journal of Obesity

JF - International Journal of Obesity

IS - 7

ER -

The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Projects

Interactions between metabolic, cognitive and reward processes in appetite

Cite this